MX2012002758A - Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas. - Google Patents

Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.

Info

Publication number
MX2012002758A
MX2012002758A MX2012002758A MX2012002758A MX2012002758A MX 2012002758 A MX2012002758 A MX 2012002758A MX 2012002758 A MX2012002758 A MX 2012002758A MX 2012002758 A MX2012002758 A MX 2012002758A MX 2012002758 A MX2012002758 A MX 2012002758A
Authority
MX
Mexico
Prior art keywords
pyrazinylpyridines
useful
treatment
proliferative diseases
compound
Prior art date
Application number
MX2012002758A
Other languages
English (en)
Inventor
Martin Sendzik
Paul A Barsanti
Keith B Pfister
James Sutton
Cheng Hu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012002758A publication Critical patent/MX2012002758A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) (ver fórmula (I)) y las sales farmacéuticamente aceptables del mismo. También se proporciona un método para utilizar un compuesto de la fórmula I para el tratamiento de una enfermedad o condición mediada por un inhibidor de CDK.
MX2012002758A 2009-09-04 2010-09-02 Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas. MX2012002758A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27593809P 2009-09-04 2009-09-04
US28496209P 2009-12-28 2009-12-28
PCT/EP2010/062881 WO2011026904A1 (en) 2009-09-04 2010-09-02 Pyrazinylpyridines useful for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
MX2012002758A true MX2012002758A (es) 2012-04-19

Family

ID=43480986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002758A MX2012002758A (es) 2009-09-04 2010-09-02 Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.

Country Status (10)

Country Link
US (1) US20120165306A1 (es)
EP (1) EP2473505A1 (es)
KR (1) KR20120076352A (es)
CN (1) CN102482265A (es)
AU (1) AU2010291199A1 (es)
BR (1) BR112012004836A2 (es)
CA (1) CA2772265A1 (es)
IN (1) IN2012DN01273A (es)
MX (1) MX2012002758A (es)
WO (1) WO2011026904A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101062A1 (en) * 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
WO2014106606A1 (en) * 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
CN105764887A (zh) 2013-09-12 2016-07-13 住友化学株式会社 含氮饱和杂环化合物
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
MX2019004602A (es) 2016-10-20 2019-06-17 Pfizer Agentes anti-proliferativos para tratar pah.
WO2020016579A2 (en) 2018-07-17 2020-01-23 Gtn Ltd Machine learning based methods of analysing drug-like molecules
CN114787142A (zh) * 2019-12-09 2022-07-22 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
GB202013419D0 (en) 2020-08-27 2020-10-14 Kuano Ltd Transition state 2020
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
WO2022247796A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN115448874A (zh) * 2021-06-09 2022-12-09 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP1330452B1 (en) * 2000-09-20 2008-11-26 Ortho-McNeil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections

Also Published As

Publication number Publication date
BR112012004836A2 (pt) 2019-09-24
EP2473505A1 (en) 2012-07-11
IN2012DN01273A (es) 2015-05-15
CA2772265A1 (en) 2011-03-10
US20120165306A1 (en) 2012-06-28
CN102482265A (zh) 2012-05-30
WO2011026904A1 (en) 2011-03-10
AU2010291199A1 (en) 2012-03-08
KR20120076352A (ko) 2012-07-09

Similar Documents

Publication Publication Date Title
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
MX2012002761A (es) Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
JO2885B1 (en) Protein kinase inhibitors
JO2848B1 (en) Organic compounds
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
UA115427C2 (uk) Бензиламінові похідні як інгібітори калікреїну плазми
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
AU2012214029A8 (en) Rorgammat inhibitors
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX346186B (es) Inhibidores de proteina cinasas.
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
JO3032B1 (ar) مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
PH12014501417A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
MX2013007497A (es) Compuestos heterociclicos adecuados para el tratamiento de dislipidemia.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal